Literature DB >> 33381115

Cytokine and Chemokine Signals of T-Cell Exclusion in Tumors.

Yu Zhang1,2, Xin-Yuan Guan2, Peng Jiang1.   

Abstract

The success of cancer immunotherapy in solid tumors depends on a sufficient distribution of effector T cells into malignant lesions. However, immune-cold tumors utilize many T-cell exclusion mechanisms to resist immunotherapy. T cells have to go through three steps to fight against tumors: trafficking to the tumor core, surviving and expanding, and maintaining the memory phenotype for long-lasting responses. Cytokines and chemokines play critical roles in modulating the recruitment of T cells and the overall cellular compositions of the tumor microenvironment. Manipulating the cytokine or chemokine environment has brought success in preclinical models and early-stage clinical trials. However, depending on the immune context, the same cytokine or chemokine signals may exhibit either antitumor or protumor activities and induce unwanted side effects. Therefore, a comprehensive understanding of the cytokine and chemokine signals is the premise of overcoming T-cell exclusion for effective and innovative anti-cancer therapies.
Copyright © 2020 Zhang, Guan and Jiang.

Entities:  

Keywords:  T-cell exclusion; cell therapy; chemokine; cytokine; immunotherapy

Mesh:

Substances:

Year:  2020        PMID: 33381115      PMCID: PMC7768018          DOI: 10.3389/fimmu.2020.594609

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  259 in total

Review 1.  IL-2: the first effective immunotherapy for human cancer.

Authors:  Steven A Rosenberg
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

2.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Authors:  Stefani Spranger; Daisy Dai; Brendan Horton; Thomas F Gajewski
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

Review 3.  The IL-4 receptor: signaling mechanisms and biologic functions.

Authors:  K Nelms; A D Keegan; J Zamorano; J J Ryan; W E Paul
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

4.  IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells.

Authors:  Daniel T Fisher; Qing Chen; Joseph J Skitzki; Jason B Muhitch; Lei Zhou; Michelle M Appenheimer; Trupti D Vardam; Emily L Weis; Jessica Passanese; Wan-Chao Wang; Sandra O Gollnick; Mark W Dewhirst; Stefan Rose-John; Elizabeth A Repasky; Heinz Baumann; Sharon S Evans
Journal:  J Clin Invest       Date:  2011-09-19       Impact factor: 14.808

5.  IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells.

Authors:  Romaine I Fernando; Marianne D Castillo; Mary Litzinger; Duane H Hamilton; Claudia Palena
Journal:  Cancer Res       Date:  2011-06-08       Impact factor: 12.701

Review 6.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

7.  Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer.

Authors:  Bernhard Mlecnik; Marie Tosolini; Pornpimol Charoentong; Amos Kirilovsky; Gabriela Bindea; Anne Berger; Matthieu Camus; Mélanie Gillard; Patrick Bruneval; Wolf-Herman Fridman; Franck Pagès; Zlatko Trajanoski; Jérôme Galon
Journal:  Gastroenterology       Date:  2009-11-10       Impact factor: 22.682

8.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

9.  CART cells are prone to Fas- and DR5-mediated cell death.

Authors:  Benjamin O Tschumi; Nina Dumauthioz; Bastien Marti; Lianjun Zhang; Evripidis Lanitis; Melita Irving; Pascal Schneider; Jean-Pierre Mach; Pedro Romero; Alena Donda
Journal:  J Immunother Cancer       Date:  2018-07-13       Impact factor: 13.751

10.  CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.

Authors:  Colin W Steele; Saadia A Karim; Joshua D G Leach; Peter Bailey; Rosanna Upstill-Goddard; Loveena Rishi; Mona Foth; Sheila Bryson; Karen McDaid; Zena Wilson; Catherine Eberlein; Juliana B Candido; Mairi Clarke; Colin Nixon; John Connelly; Nigel Jamieson; C Ross Carter; Frances Balkwill; David K Chang; T R Jeffry Evans; Douglas Strathdee; Andrew V Biankin; Robert J B Nibbs; Simon T Barry; Owen J Sansom; Jennifer P Morton
Journal:  Cancer Cell       Date:  2016-06-02       Impact factor: 38.585

View more
  18 in total

Review 1.  Exploring immunotherapy in colorectal cancer.

Authors:  Junyong Weng; Shanbao Li; Zhonglin Zhu; Qi Liu; Ruoxin Zhang; Yufei Yang; Xinxiang Li
Journal:  J Hematol Oncol       Date:  2022-07-16       Impact factor: 23.168

2.  Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.

Authors:  Yong Gu Lee; Puneeth Guruprasad; Guido Ghilardi; Raymone Pajarillo; Christopher Tor Sauter; Ruchi Patel; Hatcher J Ballard; Seok Jae Hong; Inkook Chun; Nicholas Yang; Kimberly V Amelsberg; Katherine D Cummins; Jakub Svoboda; Saar Gill; Elise A Chong; Khrystyna North; Sarah E Church; Joseph A Fraietta; Wan-Jung Chang; Simon F Lacey; Xueqing Maggie Lu; Yunlin Zhang; Kanupriya Whig; David C Schultz; Sara Cherry; James Gerson; Stephen J Schuster; Patrizia Porazzi; Marco Ruella
Journal:  Cancer Discov       Date:  2022-10-05       Impact factor: 38.272

Review 3.  Modelling the tumor immune microenvironment for precision immunotherapy.

Authors:  Nathan J Mackenzie; Clarissa Nicholls; Abby R Templeton; Mahasha Pj Perera; Penny L Jeffery; Kate Zimmermann; Arutha Kulasinghe; Tony J Kenna; Ian Vela; Elizabeth D Williams; Patrick B Thomas
Journal:  Clin Transl Immunology       Date:  2022-06-26

Review 4.  Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy.

Authors:  Bhalchandra Mirlekar
Journal:  SAGE Open Med       Date:  2022-01-25

5.  E-Cadherin Expression and Blunted Interferon Response in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Authors:  Luisa Lorenzi; Silvia Lonardi; Donatella Vairo; Andrea Bernardelli; Michela Tomaselli; Mattia Bugatti; Sara Licini; Mariachiara Arisi; Lorenzo Cerroni; Alessandra Tucci; William Vermi; Silvia Clara Giliani; Fabio Facchetti
Journal:  Am J Surg Pathol       Date:  2021-10-01       Impact factor: 6.298

6.  Biejiajian Pill Promotes the Infiltration of CD8+ T Cells in Hepatocellular Carcinoma by Regulating the Expression of CCL5.

Authors:  Xuemei Yang; Jialing Sun; Bin Wen; Yu Wang; Mingjia Zhang; Weicong Chen; Wenting Zhao; Chunyu He; Xiaodan Zhong; Yang Liu; Tong Li; Haitao Sun; Songqi He
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

7.  Systematic investigation of cytokine signaling activity at the tissue and single-cell levels.

Authors:  Peng Jiang; Yu Zhang; Beibei Ru; Yuan Yang; Trang Vu; Rohit Paul; Amer Mirza; Grégoire Altan-Bonnet; Lingrui Liu; Eytan Ruppin; Lalage Wakefield; Kai W Wucherpfennig
Journal:  Nat Methods       Date:  2021-09-30       Impact factor: 28.547

8.  Development and Validation of a CD8+ T Cell Infiltration-Related Signature for Melanoma Patients.

Authors:  Yuan Yuan; Zheng Zhu; Ying Lan; Saili Duan; Ziqing Zhu; Xi Zhang; Guoyin Li; Hui Qu; Yanhui Feng; Hui Cai; Zewen Song
Journal:  Front Immunol       Date:  2021-05-10       Impact factor: 7.561

9.  Immunology of Cell Death in Cancer Immunotherapy.

Authors:  Lorenzo Galluzzi; Abhishek D Garg
Journal:  Cells       Date:  2021-05-15       Impact factor: 6.600

10.  Proliferating CD8+ T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma.

Authors:  Ileana S Mauldin; Jasmin Jo; Nolan A Wages; Lalanthica V Yogendran; Adela Mahmutovic; Samuel J Young; Maria Beatriz Lopes; Craig L Slingluff; Loren D Erickson; Camilo E Fadul
Journal:  Cells       Date:  2021-12-01       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.